Ankylosing Spondylitis

Risankizumab May Not Be Effective in Treatment of Ankylosing Spondylitis

Risankizumab May Not Be Effective in Treatment of Ankylosing Spondylitis

Treatment with risankizumab was not effective in reducing the signs and symptoms of ankylosing spondylitis at 12 weeks.

Ankylosing Spondylitis Linked to Increased Prevalence of Left Ventricular Hypertrophy

Data strengthen the indication for performing a thorough CVD risk assessment in patients with inflammatory disorders.

Fatigue Affects Work Disability in Rheumatoid Arthritis, Ankylosing Spondylitis

Fatigue had a significant and independent effect on work disability measures in rheumatoid arthritis and ankylosing spondylitis.

Axial Psoriatic Arthritis and Ankylosing Spondylitis: Comparing Clinical, Radiologic Characteristics

It is unclear whether ankylosing spondylitis and axial psoriatic arthritis are part of a spectrum of the same disease, or whether they are separate diseases with overlapping features.

NSAID, TNFi Combination May Reduce Radiographic Progression in Ankylosing Spondylitis

Dose-related use of NSAIDs together with TNFi in patients with ankylosing spondylitis has a synergistic effect in slowing radiographic progression.

Biologic Therapy in Ankylosing Spondylitis: Insights From Social Media

Researchers used data from social media to identify concerns and perceptions regarding biologic therapies.

Tofacitinib Reduces MRI Inflammation, May Improve Outcomes in Ankylosing Spondylitis

Researchers assessed achievement of minimally important changes in SPARCC scores in biologic-naive patients with ankylosing spondylitis treated with tofacitinib or placebo.

Factors Associated With Neuropathic Pain in Ankylosing Spondylitis

A number of factors that include age, the presence of enthesitis, and depressive symptoms may be associated with neuropathic pain in ankylosing spondylitis.

Effects of Certolizumab Pegol Exposure on Pregnancy Outcomes in Women With Rheumatic Disease

Researchers sought to provide information on pregnancy outcomes, including major congenital malformations and other maternal and fetal adverse outcomes, in women treated with certolizumab pegol.

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

Nonmandatory transitioning from originator etanercept to biosimilar etanercept SB4 using a specifically designed communication strategy showed a slightly lower persistence rate and smaller decreases in disease activity.

Sign Up for Free e-newsletters